Psychiatr. pro Praxi, 2009; 10(4): 180-183

Influence of antidepressant on body weight

prof. MUDr. Eva Češková CSc
Psychiatrická klinika LF MU a FN Brno

The paper deals with weight gain during antidepressant treatment. The weight gain can be a sign of recovery or an adverse event of the



treatment: Changes in weight differ depending on which AD is used. A long-term treatment is usually associated with weight gain. On

the base of retrospective charts analysis we found that some treatment strategies used in patients hospitalized with severe depression

can lead to a more robust weight gain. The augmentation of ADs with atypical antipsychotics seems to be the most risky. Further the

knowledge about the mutual relationship between depression and metabolic syndrome is reviewed. Shortly, treatment possibilities of

obesity associated with antidepressant treatment are mentioned.

Keywords: antidepressants, weight gain, atypical antipsychotics, metabolic syndrome, obesity treatment.

Published: August 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Češková E. Influence of antidepressant on body weight. Psychiatr. praxi. 2009;10(4):180-183.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Benazzi F. Weight gain in depression remitted with antidepressants: Pharmacological or recovery effect? Psychother Psychosom 1998; 67: 271-274. Go to original source... Go to PubMed...
    2. Masand PS, Gupta S. Long-term side effects of newer-generation antidepressants: SSRIs, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry 2002; 14: 175-182. Go to original source...
    3. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000; 61(Suppl 11): 37-41. Go to original source...
    4. Fava M, Judge R, Hoog SL, et al. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry 2000; 61: 863-867. Go to original source... Go to PubMed...
    5. Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int Clin Psychopharmacol 1998; 13: 63-73. Go to original source... Go to PubMed...
    6. Himmerich H, Fulda S, Schaaf L, et al. Changes in weight and glucose tolerance during treatment with mirtazapine. Diabetes Care 2006; 29: 170-171. Go to original source...
    7. Wise TN, Perahia DG, Pangallo BA, et al. Effects of the antidepressant duloxetine on body weight: analyse of 10 clinical studies. Prim. Care Companion J Clin Psychiatry 2006; 8: 269-278. Go to original source... Go to PubMed...
    8. De Hert M, Schreurs V, Vancampfort D, Van Winkel R. Metabolic syndrome in people with schizophrenia. World Psychiatry 2009; 8: 15-22. Go to original source... Go to PubMed...
    9. Hu XH, Bull SA, Hunkeler, et al. Incidence and duration of adverse events and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry 2004; 65: 959-965. Go to original source... Go to PubMed...
    10. Zeman M, Jirák R, Žák A, et al. Metabolický syndrom a deprese - klinické vztahy. Čas. Lék. Čes. 2008; 147: 75-80.
    11. Shelton MR, Moulin P, Terra JL, Bonet F. Associations between anxiety, depression, and the metabolic syndrome. Biol Psychiatry 2007; 62: 1251-1257. Go to original source... Go to PubMed...
    12. Koponen H, Jakelainen J, Keinanen-Kiukaanniemi S, et al. Metabolic syndrome predisposes to depressive symptoms. A population-based 7-year follow-up study. J Clin Psychiatry 2008; 69: 178-182. Go to original source... Go to PubMed...
    13. Eaton WW. Epidemiologic evidence on the comorbidity of depression and diabetes. J Psychosom Res 2002; 53: 903-906. Go to original source... Go to PubMed...
    14. Talbot F, Nouwen A. A review of the relationship between depression and diabetes in adults: is there a link? Diabetes Care 2000; 23: 1556-1562. Go to original source... Go to PubMed...
    15. Capuron L, Su S, Miller AH, et al. Depressive symptoms and metabolic syndrome. Is inflammation the underlying link? Biol Psychiatry 2008; 64: 896-900. Go to original source... Go to PubMed...
    16. Papakostas GI, Ongur D, Iosifescu DV, et al. Cholesterol in mood and anxiety disorders: review of the literature and new hypothesis. Europ Neuropsychopharmacology 2004; 14: 135-142. Go to original source... Go to PubMed...
    17. Pace TW, Hu F, Miller AH. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav Immun 2007; 21: 9-19. Go to original source... Go to PubMed...
    18. Kvasnička T. Metabolické účinky endokanabinoidního systému. Čas. Lék čes. 2008; 147: 81-84.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.